The insider sales are small relative to market cap and follow a large equity grant cycle, making them consistent with routine tax-planning or diversification. Monitor for any upcoming pipeline catalysts (clinical data readouts, regulatory updates) that could explain the timing, but do not read this cluster as a bearish signal on its own.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 10 $10.42entry
- T+1 · 2mo ago −1.92%α −2.77% · $10.22
- T+5 · 2mo ago −19.00%α −19.63% · $8.44
- T+20 · 6w ago −34.74%α −37.12% · $6.80
- T+47 · todayOpen
- T+60 · in 17d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four Artiva Biotherapeutics insiders, including the CEO, COO, and CTO, sold a total of ~$477K in open-market shares over a one-week window. These sales follow a cluster of non-cash equity grants to the same executives, suggesting the sales are likely liquidity-driven (tax planning, diversification) rather than signaling a bearish view on the company's pipeline. The total dollar value is ~0.1% of the $500M market cap, falling at the low end of the trivial-to-modest range, and the historical pattern of insider buys at this company has been strongly predictive of upside, not sales. The cross-filing context shows no bearish corporate events (no earnings miss, no restructuring, no late filing) that would amplify the signal, and the actuarial verdicts confirm that insider-sale clusters without such context are not amplified. The net impact is neutral to slightly cautious, but not a material sell signal.
Key Financial Metrics
Key Facts
- CEO Fred Aslan sold 23.4K shares for ~$256K on 2026-09-08 at $10.92/share.
- COO Jennifer Bush sold 8.4K shares for ~$94K on 2026-09-03 at $11.16/share.
- CTO Christopher Horan sold 10.4K shares for ~$116K on 2026-09-03 at $11.16/share.
- CMO Subhashis Banerjee sold 1.1K shares for ~$12K on 2026-09-03 at $11.16/share.
- Total open-market sales of ~$477K represent ~0.1% of the $500M market cap, trivial by proportionality standards.
- All four executives received large non-cash equity grants (totaling ~856K shares) in the same week, consistent with a standard equity compensation cycle.
Financial Impact
Total insider sales of ~$477K, or ~0.1% of market cap, immaterial from a capital markets perspective.
Risk Factors
- Insider sales could accelerate if the stock rallies, creating overhead supply.
- No open-market insider buying in the cluster, absence of bullish insider conviction.
- Clinical-stage biotech risk: any pipeline setback could amplify the modest insider selling pattern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1789432300198 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Viewing Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers